Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio


Product Detail

Product Tags

Related Video

Feedback (2)

We have been ready to share our knowledge of internet marketing worldwide and recommend you suitable merchandise at most aggressive rates. So Profi Tools present you very best price of money and we are ready to develop alongside one another with candida IgM antibody, chemiluminescence immunoassay analyzer, Serum Amyloid A test, We intention at Ongoing system innovation, management innovation, elite innovation and market place innovation, give full play into the overall advantages, and frequently strengthen services excellent.
Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio Detail:

Product Introduction

Virusee® COVID-19 IgM Lateral Flow Assay is a lateral flow immunoassay used for the qualitative detection of Novel Coronavirus IgM antibody in human whole blood / serum / plasma samples in vitro. It is mainly used in the auxiliary clinical diagnosis of novel coronavirus pneumonia.

The novel coronavirus is a positive single-stranded RNA virus. Unlike any known coronavirus, the vulnerable population for Novel Coronavirus is generally susceptible, and it is more threatening to the elderly or people with fundamental diseases. IgM antibodies positive is an important indicator of novel coronavirus infections. Detection of novel coronavirus-specific antibodies will aid clinical diagnosis.

Characteristics

Name

COVID-19 IgM Lateral Flow Assay

Method

Lateral Flow Assay

Sample type

Blood, plasma, serum

Specification

40 tests/kit

Detection time

10 min

Detection objects

COVID-19

Stability

The kit is stable for 1 year at 2-30°C

COVID-19 IgM

Advantage

  • Rapid
    Obtain result within 10 min
  • Simple
    Visually reading result, easy to interpret
    Simple procedure, without complicated operation
  • Cost-saving
    Product can be transported and stored at room temperature, reducing costs
  • Low risk
    Testing blood sample, reducing the risk of sampling process
  • Suitable for screening on-site, bedside, outpatient

Background and principle

SARS-CoV-2 emerged as a novel virus with no available treatment option and caused a serious disaster across the world. The disease caused by this virus, “COVID-19″, announced a global pandemic on March 11, 2020. Without any proper treatment and vaccine for COVID-19, people around the world are currently experiencing a worldwide emergency affecting all societies, and it has sent billions of people into lockdown. Around the world, desperate efforts are underway to curtail this pandemic while it has resulted in the collapsing of health systems and has triggered lasting geopolitical and economic changes.

Poor diagnosis of COVID-19 has also contributed to disease severity due to stress (in case of false positive) and disease spread (in case of a false negative). A lack of RT-PCR test sampling of lower tract respiratory specimens was the main reason for the misclassification of symptomatic patients as either having COVID-19 or not. A prompt diagnosis with serological testing shows SARS-CoV-2 IgG/IgM patterns in a better and understandable way of seroconversion.

The IgG/IgM assays to detect the length and origin of humoral responses against SARS-CoV-2 is very important, and these antibodies can be detected from a few days after the onset of diseases and may remain in the body even after years of infection. In the case of COVID-19, IgM and IgG response can be observed from the second week of the disease.

Serologic assays provide quick diagnostic by avoiding PCR false positive/false negative result as well as these provide antibody pattern for estimation of strength and duration of humoral immunity.

IgM and IgG antibody detection can identify suspected cases with negative nucleic acid tests. Compared with nucleic acid detection, IgM and IgG detection may provide a quick, simple, and accurate detection method for suspected COVID-19 cases.

COVID-19 IgM Lateral Flow Assay 1
COVID-19 IgM Lateral Flow Assay 2

Test process

COVID-19 IgM Lateral Flow Assay 3

Order Information

Model

Description

Product code

VMLFA-01

40 test/kit, strip format

CoVMLFA-01


Product detail pictures:

Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio detail pictures

Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio detail pictures

Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio detail pictures


Related Product Guide:

"Sincerity, Innovation, Rigorousness, and Efficiency" will be the persistent conception of our company to the long-term to establish together with customers for mutual reciprocity and mutual gain for Newly Arrival Carbapenem-resistant NDM Detection K-Set (Lateral Flow Assay) - COVID-19 IgM Lateral Flow Assay – Genobio , The product will supply to all over the world, such as: Barbados, Greece, Poland, With a team of experienced and knowledgeable personnel, our market covers South America, the USA, the Mid East, and North Africa. Many customers have become our friends after good cooperation with us. If you have the requirement for any of our goods, make sure you contact us now. We're looking forward to hearing from you soon.
  • The company has rich resources, advanced machinery, experienced workers and excellent services, hope you keep improving and perfecting your products and service, wish you better!
    5 Stars By Carey from Marseille - 2018.10.09 19:07
    Wide range, good quality, reasonable prices and good service, advanced equipment, excellent talents and continuously strengthened technology forces,a nice business partner.
    5 Stars By Christopher Mabey from Comoros - 2018.09.19 18:37
    Write your message here and send it to us